New Treatment for Resistant Hypertension with JP Milon Quantum Genomics

Published: Feb. 5, 2019, 11:02 p.m.

JP Milon is CEO of Paris-based Quantum Genomics, a company developing a treatment for patients with hypertension that is resistant to currently available medications.\xa0 Over-represented in populations with resistant hypertension, minorities often suffer severe complications as a result of having perpetual high blood pressure.\xa0 JP discusses firibastat, Quantum Genomic's experimental drug which works by acting on the part of the brain that lowers blood pressure and could potentially help these under-served patients.

#hypertension\xa0 #cardiology\xa0 #treatmentresistance #biotech

Quantum Genomics

\xa0